Previous 10 | Next 10 |
– Annual progress report highlights the breadth of innovative and collaborative initiatives that support accessibility of RNAi therapeutics for people who can benefit worldwide – Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics co...
– Phase 2 Study will Evaluate the Safety and Efficacy of Lumasiran in Patients with Recurrent Kidney Stone Disease and Elevated Urinary Oxalate Levels – Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced tha...
– Company Expects to Initiate a Phase 1/2 Study for ALN-XDH in Gout in Early 2022, with Initial Human Data in Late 2022 – Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that the Company has submitted a c...
Alnylam Pharmaceuticals (NASDAQ:ALNY), Crispr Therapeutics (NASDAQ:CRSP), Karuna Therapeutics (NASDAQ:KRTX) and six other biopharma names are among potential M&A candidates for 2022, according to Goldman Sachs. The nine new names have been added to Goldman Sach's Healthcare Strategic Asse...
Alnylam Pharmaceuticals (NASDAQ:ALNY) has submitted a sNDA to the FDA for a label expansion of Oxlumo to include reducing plasma oxalate in advanced primary hyperoxaluria type 1 (PH1). A Type II Filing Variation for Oxlumo (lumasiran) was also submitted European Medicines Agency . The ap...
-Findings From the ILLUMINATE-C Phase 3 Study Showed Substantial Reductions in Plasma Oxalate in PH1 Patients with End-Stage Kidney Disease, Including Patients on Hemodialysis- Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced...
Direxion Launches mRNA ETF (MSGR) MSGR Offers Exposure to Rapidly Evolving mRNA Sector PR Newswire NEW YORK , Dec. 9, 2021 /PRNewswire/ -- Direxion announced today the launch of the Direxion mRNA ETF (Ticker: MSGR) . MSGR invests in companies ...
Although the Healthcare sector is having a positive year in absolute terms, that isn't the case in relative terms. Biotech stocks are having a difficult year, in spite of many of those trading at dirt-cheap valuations that don't even reflect the cash they have in-hand. It's very l...
- Recognition Marks Alnylam’s Seventh Year in a Row on this Prestigious List, and its First Time Ranking #1 - Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced it has ranked first in Boston Globe’s 2021 Top...
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that management will present company overviews at the following conferences being held virtually: Evercore ISI 4 th Annual HealthCONx Conference on Tuesday, November 30, 20...
News, Short Squeeze, Breakout and More Instantly...
Alnylam Pharmaceuticals Inc. Company Name:
ALNY Stock Symbol:
NASDAQ Market:
Alnylam Pharmaceuticals Inc. Website:
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that it will report financial results for the second quarter ending June 30, 2024 on Thursday, August 1, 2024, before the U.S. financial markets open. Management will provide an update on th...
2024-06-29 16:24:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...